Company patents
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. shows a surprising shift in its patent strategy, with its core 'Pharmaceutical Preparations' category, representing 50.9% of its portfolio, experiencing a notable decline of 13.9% in 2025 and a further 48.4% so far in 2026, suggesting a potential re-evaluation of its primary drug development focus, while 'Peptides & Proteins' has seen a dramatic 100% decline in patenting activity so far in 2026, indicating a significant deprioritization in this area.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
230 US filings (since 2023) · 3 categories · 6 themes
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Patents
Showing 1-10 of 14
Immune Checkpoint Modulation